BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35957504)

  • 1. Retrospective Study from a Single Center in Romania of 347 Renal Transplant Patients Treated with Tacrolimus, Mycophenolate, and Steroids to Evaluate the Association Between Anti-HLA Antibodies and 5-Year Graft Survival.
    Mărunţelu I; Nistor CE; Cristea BM; Rotarescu CA; Caragea AM; Tizu M; Constantinescu I
    Ann Transplant; 2022 Aug; 27():e937267. PubMed ID: 35957504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtle Changes in Tacrolimus Levels Have an Impact on Early Donor-Specific Antibodies in Kidney Transplantation.
    Henderson M; Awdishu L; Morris GP; Fabbri K; Shah M; Khan A; Kerr J
    Prog Transplant; 2023 Dec; 33(4):335-340. PubMed ID: 37941352
    [No Abstract]   [Full Text] [Related]  

  • 4. Frequency of Human Leukocyte Antigens and Donor Specific Antibodies in Long-Term Living Donor Kidney Transplantation.
    Alagoz S; Seyahi N
    Transplant Proc; 2019 Sep; 51(7):2302-2307. PubMed ID: 31358448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
    Peng ZG; Tian J
    Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA-Sensitized Patients Given Tacrolimus Once or Twice Daily During the First 2 Years After Kidney Transplant.
    Hage V; Ferrandiz I; Béllière J; Esposito L; Hebral AL; Cointault O; Del Bello A; Kamar N
    Exp Clin Transplant; 2019 Jun; 17(3):313-319. PubMed ID: 30602364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns in Tacrolimus Variability and Association with
    Piburn KH; Sigurjonsdottir VK; Indridason OS; Maestretti L; Patton MV; McGrath A; Palsson R; Gallo A; Chaudhuri A; Grimm PC
    Clin J Am Soc Nephrol; 2022 Aug; 17(8):1194-1203. PubMed ID: 35882506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients.
    Michielsen LA; van Zuilen AD; Verhaar MC; Wisse BW; Kamburova EG; Joosten I; Allebes WA; van der Meer A; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Hilbrands LB
    Nephrol Dial Transplant; 2019 Aug; 34(8):1417-1422. PubMed ID: 30561730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients.
    Lenaers JI; Christiaans MH; Voorter CE; van Hooff HP; van den Berg-Loonen EM
    Transplantation; 2006 Nov; 82(9):1142-7. PubMed ID: 17102764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies.
    Wissing KM; Fomegné G; Broeders N; Ghisdal L; Hoang AD; Mikhalski D; Donckier V; Vereerstraeten P; Abramowicz D
    Transplantation; 2008 Feb; 85(3):411-6. PubMed ID: 18322434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection.
    Abdelnoor AM; Ajib R; Chakhtoura M; Daouk M; Medawar W; Uwaydah M; Sawah SI; Khauli RB
    Immunopharmacol Immunotoxicol; 2009; 31(1):83-7. PubMed ID: 18752168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic antibodies--valuable prognostic factor for long term kidney allograft survival.
    Moise A; Nedelcu D; Toader A; Sora M; Tica A; Ferastraoaru DE; Constantinescu I
    J Med Life; 2010; 3(4):390-5. PubMed ID: 21254736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
    Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
    Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.
    Gill JS; Landsberg D; Johnston O; Shapiro RJ; Magil AB; Wu V; Tinckam K; Keown P
    Transplantation; 2010 Jan; 89(2):178-84. PubMed ID: 20098280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitors in HLA-identical living related donor kidney transplantation.
    Verghese PS; Dunn TB; Chinnakotla S; Gillingham KJ; Matas AJ; Mauer MS
    Nephrol Dial Transplant; 2014 Jan; 29(1):209-18. PubMed ID: 24414376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.